850881-86-6Relevant articles and documents
Promising new inhibitors of tyrosyl-DNA phosphodiesterase I (Tdp 1) combining 4- arylcoumarin and monoterpenoid moieties as components of complex antitumor therapy
Ayine-tora, Daniel M.,Chand, Raina,Chepanova, Arina A.,Ilina, Ekaterina S.,Kaledin, Vasily I.,Khomenko, Tatyana M.,Korchagina, Dina V.,Lavrik, Olga I.,Leung, Ivanhoe K. H.,Nikolin, Valeriy P.,Patel, Jinal,Popova, Nelly A.,Reynisson, Jóhannes,Salakhutdinov, Nariman F.,Volcho, Konstantin P.,Zakharenko, Alexandra L.,Zakharova, Olga D.
, (2020/01/08)
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an important DNA repair enzyme in humans, and a current and promising inhibition target for the development of new chemosensitizing agents due to its ability to remove DNA damage caused by topoisomerase 1 (Top1) poisons such as topotecan and irinotecan. Herein, we report our work on the synthesis and characterization of new Tdp1 inhibitors that combine the arylcoumarin (neoflavonoid) and monoterpenoid moieties. Our results showed that they are potent Tdp1 inhibitors with IC50 values in the submicromolar range. In vivo experiments with mice revealed that compound 3ba (IC50 0.62 μM) induced a significant increase in the antitumor effect of topotecan on the Krebs-2 ascites tumor model. Our results further strengthen the argument that Tdp1 is a druggable target with the potential to be developed into a clinically-potent adjunct therapy in conjunction with Top1 poisons.
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics
Chen, Yin,Wang, Songlin,Xu, Xiangqing,Liu, Xin,Yu, Minquan,Zhao, Song,Liu, Shicheng,Qiu, Yinli,Zhang, Tan,Liu, Bi-Feng,Zhang, Guisen
, p. 4671 - 4690 (2013/07/19)
The discovery and synthesis of potential and novel antipsychotic coumarin derivatives, associated with potent dopamine D2, D3, and serotonin 5-HT1A and 5-HT2A receptor properties, are the focus of the present article. The most-promising derivative was 7-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy) -4-methyl-8-chloro-2H-chromen-2-one (17m). This derivative possesses unique pharmacological features, including high affinity for dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors. Moreover, it possesses low affinity for 5-HT2C and H1 receptors (to reduce the risk of obesity associated with chronic treatment) and hERG channels (to reduce the incidence of torsade des pointes). In animal models, compound 17m inhibited apomorphine-induced climbing behavior, MK-801-induced hyperactivity, and the conditioned avoidance response without observable catalepsy at the highest dose tested. Further, fewer preclinical adverse events were noted with 17m compared with risperidone in assays that measured prolactin secretion and weight gain. Acceptable pharmacokinetic properties were also noted with 17m. Taken together, 17m may constitute a novel class of drugs for the treatment of schizophrenia.
Substituted coumarins as potent 5-lipoxygenase inhibitors
Grimm, Erich L.,Brideau, Christine,Chauret, Nathalie,Chan, Chi-Chung,Delorme, Daniel,Ducharme, Yves,Ethier, Diane,Falgueyret, Jean-Pierre,Friesen, Richard W.,Guay, Jocelyne,Hamel, Pierre,Riendeau, Denis,Soucy-Breau, Chantal,Tagari, Philip,Girard, Yves
, p. 2528 - 2531 (2007/10/03)
Leukotriene biosynthesis inhibitors have potential as therapeutic agents for asthma and inflammatory diseases. A novel series of substituted coumarin derivatives has been synthesized and the structure-activity relationship was evaluated with respect to th
